Comparison Of Efficacy And Safety Of Biosimilar Ct-P10 To Rituximab In Patients With Previously Untreated Low Tumor Burden Follicular Lymphoma (Ltbfl): A Randomized Phase Iii Study

Background: CT-P10 is the first biosimilar to innovator rituximab (RTX) approved for all indications by the European Medicines Agency. The pharmacokinetics (PK) equivalence and non-inferior efficacy of CT-P10 compared with RTX in patients with newly diagnosed advanced follicular lymphoma (FL) was previously demonstrated when used with combination chemotherapy of cyclophosphamide, vincristine and prednisone (CVP) (Kim WS et al,. 2017).